Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 92

Sort by

Sort Order Select

Journal Articles

Post-transplant cyclophosphamide vs tacrolimus/methotrexate: Improved GRFS, reduced NRM, and less severe GVHD in myeloablative HLA-matched allogeneic transplantation

Blood (2025) 146 (Supplement 1): 2494.

https://doi.org/10.1182/blood-2025-2494

Published: 2025

Journal Articles

Superior efficacy and persistence of Orca-T-allogeneic CAR19/22 versus autologous CAR19/22 in high-risk adult B-ALL

Blood (2025) 146 (Supplement 1): 514.

https://doi.org/10.1182/blood-2025-514

Published: 2025

Journal Articles

Safety and efficacy of BCMA directed CAR-T therapy in older patients (Aged ≥ 75) with relapsed or refractory multiple myeloma (RRMM)

Blood (2025) 146 (Supplement 1): 6375.

https://doi.org/10.1182/blood-2025-6375

Published: 2025

Journal Articles

Allogeneic HSC and regulatory T cell (Orca-T) engineered cell therapy following reduced intensity conditioning: Results of a single center Phase 1 study

Blood (2025) 146 (Supplement 1): 111.

https://doi.org/10.1182/blood-2025-111

Published: 2025

Journal Articles

Rapid peak CAR-T expansion is associated with delayed neurotoxicity following ciltacabtagene autoleucel in multiple myeloma

Blood (2025) 146 (Supplement 1): 96.

https://doi.org/10.1182/blood-2025-96

Published: 2025

Journal Articles

Patients with TP53-mutated AML/MDS without complex or monosomal karyotype can achieve durable survival benefits with allogeneic HCT

Blood (2025) 146 (Supplement 1): 2525.

https://doi.org/10.1182/blood-2025-2525

Published: 2025

Journal Articles

Enhancing the safety of ciltacabtagene autoleucel in relapsed multiple myeloma (MM): Identification of potentially modifiable risk-factors associated with delayed neurotoxicity and non-relapse mortality

Surbhi Sidana, Brett Reid, Danai Dima, Lauren Peres, Mahmoud Gaballa, Rahul Banerjee, Oren Pasvolsky, Aimaz Afrough, Christen Dillard, Christopher Ferreri, Shebli Atrash, Cindy Varga, Andrew Portuguese, Masooma Rana, Hitomi Hosoya, Lekha Mikkilineni, Vanna Hovanky, Saurabh Zanwar, Nilesh Kalariya, Damian Mikulski, Charlotte Wagner, Christopher Cahoon, Omar Alexis Castaneda Puglianini, Gabriel De Avila, Christian Gordillo, Eli Zolotov, Ariel Grajales-Cruz, Utkarsh Goel, Aishwarya Sannareddy, Jeries Kort, Raffaella Cassano, Shonali Midha, James Davis, Rebecca Gonzalez, Megan Herr, Zhuoer Xie, Hamza Hassan, Sneha Purvey, Marcus Geer, Kimberly Green, Fabiana Perna, Hien Liu, Taiga Nishihori, Jack Khouri, Shahzad Raza, Faiz Anwer, Susan Bal, Omar Nadeem, Ciara Louise Freeman, Leyla Shune, Ran Reshef, Kenneth Shain, Melissa Alsina, Rachid Baz, Douglas Sborov, Saurabh Dahiya, Frederick Locke, David Miklos, Peter Voorhees, Larry Anderson, Luciano Costa, Noa Biran, Shaji Kumar, Yi Lin, Krina Patel, Doris Hansen

Blood (2025) 146 (Supplement 1): 1034.

https://doi.org/10.1182/blood-2025-1034

Published: 2025

Journal Articles

Patient-reported outcomes (PROs) with lisocabtagene maraleucel (liso-cel) in patients with third line or later (3L+) R/R MZL from the Phase 2 TRANSCEND FL study

Reem Karmali, Franck Morschhauser, Koji Izutsu, Lia Palomba, Kirit Ardeshna, Brian Hill, Manali Kamdar, Stephen J. Schuster, Antonio Pinto, Saurabh Dahiya, Merav Bar, Maria Strocchia, Jinender Kumar, Jeremy Abramson

Blood (2025) 146 (Supplement 1): 709.

https://doi.org/10.1182/blood-2025-709

Published: 2025

Journal Articles

Redefining post-CD19 CAR T-cell surveillance with ctdna: Real-world insights from post- axi-cel and liso-cel therapy

Snegha Ananth, Jayasindhu Mallampet, Betty Chang, Neha Agarwal, Katherine Kong, Bita Sahaf, Juan Carlos Suarez Serrato, Ilan Kirsch, Allison Jacob, Heidi Simmons, Lik Wee Lee, Crystal Mackall, Wen-Kai Weng, Sushma Bharadwaj, Melody Smith, Saurabh Dahiya, David Miklos, Matthew Frank

Blood (2025) 146 (Supplement 1): 941.

https://doi.org/10.1182/blood-2025-941

Published: 2025

Journal Articles

From response to rupture: Evaluating GI perforation after CD19 CAR‑T in LBCL

Arash Velayati, Masooma Rana, Alexandria Jensen, Dasom (Caroline) Lee, Nima Ghalehsari, Anmol Goyal, Theresa Latchford, William Wang, Eric Heng, Wen-Kai Weng, Melody Smith, Sushma Bharadwaj, Matthew Frank, David Miklos, Saurabh Dahiya

Blood (2025) 146 (Supplement 1): 2771.

https://doi.org/10.1182/blood-2025-2771

Published: 2025

Journal Articles

Double-dose axicabtagene ciloleucel (Axi-Cel-2) as second-line therapy for high-risk relapsed or refractory large B-cell lymphoma (r/rLBCL): Interim results from a Phase 1b study

Blood (2025) 146 (Supplement 1): 671.

https://doi.org/10.1182/blood-2025-671

Published: 2025

Journal Articles

Rapcabtagene autoleucel (YTB323) for patients with first line high-risk large B-cell lymphoma: Phase II interim results

Blood (2025) 146 (Supplement 1): 670.

https://doi.org/10.1182/blood-2025-670

Published: 2025

Journal Articles

Validated PET-CT metabolic tumor volume threshold identifies high-risk relapsed/refractory LBCL and predicts 12-month toxicity-free progression-free survival Post–CAR-T therapy

Blood (2025) 146 (Supplement 1): 397.

https://doi.org/10.1182/blood-2025-397

Published: 2025

Journal Articles

Association between cilta-cel dose and efficacy and toxicity outcomes for patients with Relapsed/Refractory multiple myeloma (RRMM): A real-world analysis from the US multiple myeloma immunotherapy consortium

Ran Reshef, Alexandria Jensen, Christian Gordillo, Brett Reid, Danai Dima, Lauren Peres, Mahmoud Gaballa, Rahul Banerjee, Oren Pasvolsky, Aimaz Afrough, Christen Dillard, Christopher Ferreri, Shebli Atrash, Cindy Varga, Andrew Portuguese, Masooma Rana, Hitomi Hosoya, Lekha Mikkilineni, Vanna Hovanky, Saurabh Zanwar, Nilesh Kalariya, Damian Mikulski, Charlotte Wagner, Christopher Cahoon, Omar Puglianini, Gabriel De Avila, Eli Zolotov, Evguenia Bhurtel, Ariel Grajales-Cruz, Utkarsh Goel, Aishwarya Sannareddy, Jeries Kort, Raffaella Cassano, Shonali Midha, James Davis, Rebecca Gonzalez, Megan Herr, Zhuoer Xie, Hamza Hassan, Sneha Purvey, Marcus Geer, Kimberly Green, Fabiana Perna, Hien Liu, Taiga Nishihori, Jack Khouri, Shahzad Raza, Faiz Anwer, Susan Bal, Omar Nadeem, Ciara Louise Freeman, Leyla Shune, Kenneth Shain, Melissa Alsina, Rachid Baz, Douglas Sborov, Saurabh Dahiya, Frederick Locke, David Miklos, Peter Voorhees, Larry Anderson, Luciano Costa, Noa Biran, Shaji Kumar, Yi Lin, Krina Patel, Doris Hansen, Surbhi Sidana

Blood (2025) 146 (Supplement 1): 134.

https://doi.org/10.1182/blood-2025-134

Published: 2025

Journal Articles

Non-response to bridging therapy prior to CAR-T is associated with increased toxicity and adverse outcomes in Relapsed/Refractory multiple myeloma (RRMM)

Blood (2025) 146 (Supplement 1): 4586.

https://doi.org/10.1182/blood-2025-4586

Published: 2025

Journal Articles

Pre-treatment CD19 antigen density and multi-antigen profiling by calibrated quantitative flow cytometry correlates with CAR T efficacy in LBCL

Blood (2025) 146 (Supplement 1): 5882.

https://doi.org/10.1182/blood-2025-5882

Published: 2025

Journal Articles

CD22-directed CAR-T cells induce complete remissions in high-risk follicular and Mantle Cell Lymphoma with limited neurotoxicity

Blood (2025) 146 (Supplement 1): 4159.

https://doi.org/10.1182/blood-2025-4159

Published: 2025

Journal Articles

A Phase 1 study of KITE-753 or KITE-363 in patients with relapsed/refractory B-cell lymphoma: Initial safety and preliminary efficacy of KITE-753 and updated results of KITE-363

Blood (2025) 146 (Supplement 1): 265.

https://doi.org/10.1182/blood-2025-265

Published: 2025

Journal Articles

ZUMA-25 preliminary analysis: A Phase 2 study of brexucabtagene autoleucel (brexu-cel) in patients (Pts) with relapsed/refractory (R/R) burkitt lymphoma (BL), substudy C

Blood (2025) 146 (Supplement 1): 569.

https://doi.org/10.1182/blood-2025-569

Published: 2025

Journal Articles

CD22-CAR T cell multiomic features linked to patient outcomes in CD19-CAR resistant large B cell lymphoma

Blood (2025) 146 (Supplement 1): 566.

https://doi.org/10.1182/blood-2025-566

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Post-transplant cyclophosphamide vs tacrolimus/methotrexate: Improved GRFS, reduced NRM, and less severe GVHD in myeloablative HLA-matched allogeneic transplantation

Superior efficacy and persistence of Orca-T-allogeneic CAR19/22 versus autologous CAR19/22 in high-risk adult B-ALL

Safety and efficacy of BCMA directed CAR-T therapy in older patients (Aged ≥ 75) with relapsed or refractory multiple myeloma (RRMM)

Allogeneic HSC and regulatory T cell (Orca-T) engineered cell therapy following reduced intensity conditioning: Results of a single center Phase 1 study

Rapid peak CAR-T expansion is associated with delayed neurotoxicity following ciltacabtagene autoleucel in multiple myeloma

Patients with TP53-mutated AML/MDS without complex or monosomal karyotype can achieve durable survival benefits with allogeneic HCT

Enhancing the safety of ciltacabtagene autoleucel in relapsed multiple myeloma (MM): Identification of potentially modifiable risk-factors associated with delayed neurotoxicity and non-relapse mortality

Patient-reported outcomes (PROs) with lisocabtagene maraleucel (liso-cel) in patients with third line or later (3L+) R/R MZL from the Phase 2 TRANSCEND FL study

Redefining post-CD19 CAR T-cell surveillance with ctdna: Real-world insights from post- axi-cel and liso-cel therapy

From response to rupture: Evaluating GI perforation after CD19 CAR‑T in LBCL

Double-dose axicabtagene ciloleucel (Axi-Cel-2) as second-line therapy for high-risk relapsed or refractory large B-cell lymphoma (r/rLBCL): Interim results from a Phase 1b study

Rapcabtagene autoleucel (YTB323) for patients with first line high-risk large B-cell lymphoma: Phase II interim results

Validated PET-CT metabolic tumor volume threshold identifies high-risk relapsed/refractory LBCL and predicts 12-month toxicity-free progression-free survival Post–CAR-T therapy

Association between cilta-cel dose and efficacy and toxicity outcomes for patients with Relapsed/Refractory multiple myeloma (RRMM): A real-world analysis from the US multiple myeloma immunotherapy consortium

Non-response to bridging therapy prior to CAR-T is associated with increased toxicity and adverse outcomes in Relapsed/Refractory multiple myeloma (RRMM)

Pre-treatment CD19 antigen density and multi-antigen profiling by calibrated quantitative flow cytometry correlates with CAR T efficacy in LBCL

CD22-directed CAR-T cells induce complete remissions in high-risk follicular and Mantle Cell Lymphoma with limited neurotoxicity

A Phase 1 study of KITE-753 or KITE-363 in patients with relapsed/refractory B-cell lymphoma: Initial safety and preliminary efficacy of KITE-753 and updated results of KITE-363

ZUMA-25 preliminary analysis: A Phase 2 study of brexucabtagene autoleucel (brexu-cel) in patients (Pts) with relapsed/refractory (R/R) burkitt lymphoma (BL), substudy C

CD22-CAR T cell multiomic features linked to patient outcomes in CD19-CAR resistant large B cell lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only